Skip to Content


Agency Information Collection Activities; Submission for OMB Review; Comment Request; Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 ( the PRA).


Submit written comments on the collection of information by April 7, 2003.


Submit written comments on the collection of information to Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St., NW., rm. 10235, Washington, DC, 20503, Attention: Stuart Shapiro, Desk Officer for FDA.

Start Further Info


Denver Presley, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-26, Rockville, MD 20857, 301-827-1472.

End Further Info End Preamble Start Supplemental Information


In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance:

Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report—21 CFR Part 510 (OMB Control Number 0910-0012)—Extension

In response to a 60-day notice that published in the Federal Register of September 5, 2002 (67 FR 56846), the agency received four sets of comments. Two sets of comments were from a pharmaceutical company and two were from individuals. A discussion of the comments with the Center for Veterinary Medicine's response follows:

The two individual comments pertained to a complaint concerning a veterinary product and the elimination of antibacterial soaps. These comments are not germane to this collection of information.

Four comments pertained to the interim final rule for records and reports (21 CFR 514.80) that published February 4, 2002 (67 FR 5046), which is not the subject of this Federal Register notice. The closing date for receiving comments on the interim final rule was April 5, 2002. These comments were submitted on November 4, 2002 and thus, FDA will not respond. Further, the substance of these comments were submitted in response to the Interim Final Rule and will be addressed in the Final Rule for Records and Reports.

Three comments asked FDA to increase the amount of time for investigating, gathering, and processing information and data for Form FDA 1932. One comment estimated that the burden estimate should be increased by as much as 1 to 1.75 hours for product defects. Another comment estimated that the burden estimate should be increased from 0.25 to 1 hours. The third comment stated that it would take close to 2 hours to investigate, collect, conduct quality control, and record the information.

FDA will increase the burden for the Form FDA 1932 from 1 hour to 2 hours. This will increase the total burden hours for the Form FDA 1932 from 18,385 hours to 36,770 hours.

Section 512(l) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(i)), 21 CFR 510.300, 510.301, and 510.302 require that applicants of approved NADA's submit within 15-working days of receipt, complete records of reports of certain Start Printed Page 11118adverse drug reactions and unusual failure of new animal drugs. Other reporting requirements of adverse reactions to these drugs must be reported annually or semi-annually in a specific format. This continuous monitoring of approved new animal drugs, affords the primary means by which FDA obtains information regarding potential problems in safety and effectiveness of marketed animal drugs and potential manufacturing problems. Data already on file with FDA is not adequate because animal drug effects can change over time and less apparent effects may take years to manifest themselves. Reports are reviewed along with those previously submitted for a particular drug to determine if any change is needed in the product or labeling, such as package insert changes, dosage changes, additional warnings or contraindications, or product reformulation.

Adverse reaction reports are required to be submitted by the drug manufacturer on FDA Forms 1932 or 1932a (voluntary reporting form), following complaints from animal owners or veterinarians. Likewise, product defects and lack of effectiveness complaints are submitted to FDA by the drug manufacturer following their own detection of a problem or complaints from product users or their veterinarians using forms FDA Forms 1932 and 1932a. Form FDA-2301 is available for the required transmittal of periodic reports and promotional material for new animal drug applications.

FDA estimates the burden for this collection of information as follows:

Table 1.—Estimated Annual Reporting Burden1

Form No.21 CFR SectionNo. of RespondentsAnnual Frequency per ResponseTotal Annual ResponsesHours per ResponseTotal hours
Form FDA 2301510.302(a)19010.942,0790.51,040
Form FDA 1932510.302(b)19096.7618,3852.036,770
Form FDA 1932a (voluntary)510.302(b)1001.01001.0100
Total Burden Hours37,910
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

Table 2.—Estimated Annual Recordkeeping Burden1

21 CFR SectionNo. of RecordkeepersAnnual Frequency of RecordkeepingTotal annual responseHours per RecordkeeperTotal hours
510.300(a) and 510.301(a)19013.162,07910.3521,518
510.300(b) and 510.301(b)19094.7418,3850.509,193
Total Burden Hours30,711
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

The estimate of the times required for record preparation and maintenance is based on agency communication with industry. Other information needed to calculate the total burden hours (i.e., adverse drug reaction, lack of effectiveness, and product defect reports) are derived from agency records and experience.

Start Signature

Dated: February 21, 2003.

William K. Hubbard,

Associate Commissioner for Policy and Planning.

End Signature End Supplemental Information

[FR Doc. 03-5355 Filed 3-6-03; 8:45 am]